Tuesday 14 April 2015

U.S. FDA panel favors new safety information on AstraZeneca's Onglyza

A sign is seen at an AstraZeneca site in Macclesfield AstraZeneca Plc's diabetes drug Onglyza should include new safety information about the risk of heart failure, an advisory panel to the U.S. Food and Drug Administration concluded on Tuesday. The panel voted overwhelmingly that the drug's label should be changed to add information about an increased heart failure risk, but did not express concern about the overall cardiovascular risk profile of the drug. The FDA is not obliged to follow the advice of its advisory panels but typically does so.




via Health News Headlines - Yahoo News Read More Here..

No comments:

Post a Comment